# US 2016/0257934 A1 · Reprogramming bone endothelial cells for use in bone angiogenesis and osteogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257934 A1
- Document ID: US20160257934A1
- Status: Published application
- Kind: A1
- Application number: 15/029,186
- Filed: 2014-10-14
- Published: 2016-09-08
- Earliest claimed: 2013-10-14
- Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
- Applicants: Max-Planck-Gesellschaft Zur FöRderung Der Wissenschaften E.V.
- Inventors: Ralf H. Adams; Anjali Kusumbe; Saravana Ramasamy
- Web page: https://patentgrep.com/patent/US20160257934A1

## CPC

- C12N 5/0654: {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}
- C12N 5/069: {Vascular Endothelial cells}
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- G01N 33/56966: {Animal cells}
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/42: Notch; Delta; Jagged; Serrate
- C12N 2501/999: Small molecules not provided for elsewhere
- C12Q 2600/158: Expression markers
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a factor for reprogramming bone endothelial cells to promote bone angiogenesis and osteogenesis as well as to an ex vivo method for reprogramming a bone endothelial cell to achieve cells able to mediate bone angiogenesis and osteogenesis. The subtype of bone endothelial cells mediating bone angiogenesis and osteogenesis express CD31 and Endomucin as markers.

## Claims

### Claim 1

A factor generating type H bone endothelial cells for use in promoting bone angiogenesis and osteogenesis.

### Claim 2 (depends on 1)

The factor according to claim 1 for reprogramming type L bone endothelial cells to type H bone endothelial cells for use in promoting bone angiogenesis and osteogenesis.

### Claim 3 (depends on 1, 2)

The factor according to claim 1 or 2 for the use in the treatment of osteoporoses or promotion of bone fracture healing.

### Claim 4 (depends on 1, 2, 3)

The factor according to claim 1 or 2 or 3, wherein the factor increases the stability or biological activity of HIF-1α.

### Claim 5 (depends on 1, 2, 3, 4)

The factor according to any one of claims 1-4, wherein the factor is a Prolyl-4-hydroxylase inhibitor.

### Claim 6 (depends on 1, 2, 3)

The factor according to claim 1 or 2 or 3, wherein the factor activates Notch-signaling.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The factor according to any one of claims 1-5, wherein the factor is selected from the group consisting of active HIF-1alpha, factors inhibiting VHL, factors inhibiting E3 ubiquitin protein ligase, cobalt chloride, ciclopirox olamine, L-mimosine, dimethyloxalylglycine, 3,4-dihydoxybenzoate and (N′-{5-[Acetyl(hydroxy)amino]pentyl]-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccin amide).

### Claim 8 (depends on 1, 2, 3, 6)

The factor according to any one of claim 1-3 or 6, wherein the factor is selected from the group consisting of immobilized Dll4/Fc fusion protein, a soluble Jagged1 peptide activating Dll4-Notch signaling, activated intracellular domaine of Notch, and a factor inactivating an enzyme able to destruct active Notch.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

An ex vivo method for generating a type H bone endothelial cell comprising the step of:
contacting an isolated cell with a factor according to any one of claims 1-8.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

An ex vivo method for reprogramming a type L bone endothelial cell to a type H endothelial cell comprising the step of:
contacting an isolated cell with a factor according to any one of claims 1-8.

### Claim 11

An ex vivo method for reprogramming a type L bone endothelial cell to a type H endothelial cell comprising the step of:
increasing the stability or biological activity of HIF-1α in an isolated cell or activating Notch-signaling in said isolated cell.

### Claim 12

Method for isolating bone endothelial cells able to mediate bone angiogenesis and osteogenesis.

### Claim 13 (depends on 9, 10, 11, 12)

A bone endothelial cell obtained by the method according to any one of claims 9-12.

### Claim 14

Use of CD31 and Endomucin as marker for a type H bone endothelial cells which mediate growth of bone vasculature.

### Claim 15

A method of determining a subtype of bone endothelial cells mediating growth of bone vasculature, comprising:
measuring the expression level CD31 and Endomucin in a bone endothelial cell, wherein an increased CD31 and Endomucin expression level is indicative for the subtype of bone endothelial cells mediating growth of bone vasculature.
